Lydase (for injections)
Lydase (for injections) Uses, Dosage, Side Effects, Food Interaction and all others data.
Lydase (for injections) is a dispersion agent, which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. Hyaluronic acid is also present in the capsules of type A and C hemolytic streptococci. Lydase (for injections) hydrolyzes hyaluronic acid by splitting the glucosaminidic bond between C1 of an N-acetylglucosamine moiety and C4 of a glucuronic acid moiety. This temporarily decreases the viscosity of the cellular cement and promotes dispersion of injected fluids or of localized transudates or exudates, thus facilitating their absorption. Lydase (for injections) cleaves glycosidic bonds of hyaluronic acid and, to a variable degree, some other acid mucopolysaccharides of the connective tissue. The activity is measured in vitro by monitoring the decrease in the amount of an insoluble serum albumin-hyaluronic acid complex as the enzyme cleaves the hyaluronic acid component.
| Trade Name | Lydase (for injections) |
| Availability | Prescription only |
| Generic | Hyaluronidase |
| Hyaluronidase Other Names | Hialuronidasa, Hyaluronidase, Hyaluronidase (bovine), Hyaluronidase bovine, hyaluronidase-fihj, hyaluronidase-zzxf, Hyaluronidase, bovine, Hyaluronidasum, Hyaluronoglucosaminidase |
| Related Drugs | dexrazoxane, Amphadase, Hylenex, Vitrase, Hydase |
| Type | |
| Protein binding | Data regarding the protein binding of hyaluronidase are not readily available. |
| Groups | Approved |
| Therapeutic Class | Intravenous fluid preparations |
| Manufacturer | |
| Available Country | Russia |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Lydase (for injections) recombinant is a tissue permeability modifier used as an adjuvant-
- In subcutaneous fluid administration for achieving hydration
- To increase the dispersion and absorption of other injected drugs
- In subcutaneous urography for improving resorption of radiopaque agents
Lydase (for injections) is also used to associated treatment for these conditions: Parenteral rehydration therapy, Parenteral drug administration, Subcutaneous urography
How Lydase (for injections) works
Lydase (for injections) cleaves hyaluronic acid at the glucosaminidic bond between C1 of glucosamine and C4 of glucuronic acid. Hyaluronic acid is a key component of the extracellular matrix. Injection of hyaluronidase with other fluids, drugs, or radiopaque agents improves the ability of these other compounds to permeate the extracellular space more easily.
Dosage
Lydase (for injections) dosage
Inject 150 units Lydase (for injections) recombinant prior to subcutaneous fluid administration. It will facilitate absorption of 1,000 mL or more of solution. The dosage of subcutaneous fluids administered is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations. The rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion
Increasing dispersion and absorption of injected drugs: Add 50-300 units (most typically 150 U) Lydase (for injections) recombinant to the injection solution.
Subcutaneous Urography: Inject 75 units Lydase (for injections) recombinant subcutaneously over each scapula, followed by injection of the contrast medium at the same sites
Side Effects
The following adverse reactions have been identified during post-approval use of hyaluronidase products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The most frequently reported adverse reactions have been mild local injection site reactions such as erythema and pain. Lydase (for injections) has been reported to enhance the adverse reactions associated with co-administered drug products. Edema has been reported most frequently in association with subcutaneous fluid administration. Allergic reactions (urticaria or angioedema) have been reported in less than 0.1% of patients receiving hyaluronidase. Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely.
Toxicity
Data regarding overdose of hyaluronidase is not readily available. In the even of an overdose, treat patients with symptomatic and supportive measures.
Precaution
Spread of Localized Infection: Lydase (for injections) should not be injected into or around an infected or acutely inflamed area because of the danger of spreading a localized infection. Lydase (for injections) should not be used to reduce the swelling of bites or stings.
Ocular Damage: Lydase (for injections) should not be applied directly to the cornea. It is not for topical use.
Enzyme Inactivation with Intravenous Administration: Lydase (for injections) recombinant should not be administered intravenously. Its effects relative to dispersion and absorption of other drugs are not produced when it is administered intravenously because the enzyme is rapidly inactivated.
Interaction
It is recommended that appropriate references be consulted regarding physical or chemical incompatibilities before adding Lydase (for injections) recombinant to a solution containing another drug.
Food Interaction
No interactions found.Lydase (for injections) Drug Interaction
Minor: aspirin, aspirin, hydrocortisone, hydrocortisoneUnknown: epinephrine, epinephrine, multivitamin, multivitamin, sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprim, methadone, methadone, morphine, morphine, acetaminophen, acetaminophen, ascorbic acid, ascorbic acid, cholecalciferol, cholecalciferol
Volume of Distribution
Data regarding the volume of distribution of hyaluronidase are not readily available.
Elimination Route
Data regarding the absorption of hyaluronidase are not readily available.
Half Life
Lydase (for injections) has a half life of two minutes, but a duration of action of 24-48 hours due to its high potency.
Clearance
Data regarding the clearance of hyaluronidase are not readily available.
Elimination Route
After nonspecific proteolysis, the amino acids from protein drugs are reused for protein synthesis or further broken down and eliminated by the kidneys.
Pregnancy & Breastfeeding use
Pregnancy Category C. It is also not known whether Lydase (for injections) recombinant can cause fetal harm when administered to a pregnant woman. Lydase (for injections) recombinant should be given to a pregnant woman only if clearly needed.
Nursing Mothers: It is not known whether hyaluronidase is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when hyaluronidase is administered to a nursing woman
Contraindication
Lydase (for injections) recombinant is contraindicated in patients with known hypersensitivity to hyaluronidase or any of the excipients in Lydase (for injections) recombinant. A preliminary skin test for hypersensitivity to Lydase (for injections) recombinant can be performed. The skin test is made by an intradermal injection of approximately 0.02 mL (3 Units) of a 150 Unit/mL solution. A positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes and accompanied by localized itching. Transient vasodilation at the site of the test, i.e., erythema, is not a positive reaction. Discontinue Lydase (for injections) recombinant if sensitization occurs.
Special Warning
Pediatric Use: Clinical hydration requirements for children can be achieved through administration of subcutaneous fluids facilitated with Lydase (for injections) recombinant.
Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.
Storage Condition
Store unopened in a refrigerator at 2° to 8°C. DO NOT FREEZE.
Innovators Monograph
You find simplified version here Lydase (for injections)
